Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02574663 |
Title | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors |
Recruitment | Completed |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | TG Therapeutics, Inc. |
Indications | |
Therapies | |
Age Groups: | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
TG Therapeutics Trial Site | Nashville | Tennessee | 37203 | United States | Details |